1		
2	93rd General Assembly A Bill	
3	Regular Session, 2021 SENATE BI	LL 176
4		
5	By: Senator D. Wallace	
6	By: Representative Bragg	
7		
8	For An Act To Be Entitled	
9	AN ACT TO ALLOW PHARMACISTS TO TREAT CERTAIN HEALTH	
10	CONDITIONS; AND FOR OTHER PURPOSES.	
11		
12		
13	Subtitle	
14	TO ALLOW PHARMACISTS TO TREAT CERTAIN	
15	HEALTH CONDITIONS.	
16		
17		
18	BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:	
19		
20	SECTION 1. DO NOT CODIFY. <u>Purpose</u> .	
21	It is the purpose of this act to authorize pharmacists in Arkansas	<u>to</u>
22	test and screen for health conditions that the Centers for Medicare and	
23	Medicaid Services has determined qualify for a waiver under the federal	
24	Clinical Laboratory Improvement Amendments of 1988, the federal regulati	<u>ons</u>
25	adopted, or any established screening procedures that can safely be perf	ormed
26	by a pharmacist.	
27		
28	SECTION 2. Arkansas Code § $17-92-101(17)(A)(x)$, concerning the	
29	definition of "practice of pharmacy", is amended to read as follows:	
30	(x) <u>(a)</u> Providing pharmacy care; and.	
31	(b) A pharmacist may treat the following	
32	conditions within the framework of a written protocol:	
33	(1) Influenza;	
34	(2) Pharynigitis caused by streptoc	<u>occus</u>
35	<u>A;</u>	
36	<u>(3) Lice;</u>	

1	(4) Skin conditions, such as ringworm,
2	insect bites, and athlete's foot;
3	<pre>(5) Cold sores;</pre>
4	(6) Allergic rhinitis;
5	(7) Motion sickness; and
6	(8) Medication required for travel
7	including antimalarial prescription.
8	(c) A pharmacist shall only treat conditions
9	for which the pharmacist has tested and that are approved under this
10	subdivision $(17)(A)(x)(c)$.
11	(d)(1) The Arkansas State Board of Pharmacy,
12	with consultation with the Arkansas State Medical Board, shall adopt by rule
13	a formulary of medicinal drugs that a pharmacist may prescribe for treatment
14	of conditions approved under this subdivision $(17)(A)(x)(d)$ and an
15	accompanying treatment protocol.
16	(2) The formulary shall include
17	medicinal drugs approved by the United States Food and Drug Administration
18	which are indicated for treatment of these conditions, including without
19	limitation any over-the-counter medication.
20	(3) The formulary shall not include any
21	controlled substance in Schedule I-IV or 21 U.S.C. § 812, as existing on
22	January 1, 2021; and
23	
24	SECTION 3. Arkansas Code Title 17, Chapter 92, Subchapter 1, is
25	amended to add an additional section to read as follows:
26	17-92-118. Point-of-care treatment.
27	A pharmacist who tests for conditions under § 17-92-101(17)(A)(x)
28	shall:
29	(1) Hold a license to practice pharmacy in this state;
30	(2) Report a diagnosis or suspected existence of influenza to
31	the Department of Health;
32	(3) Furnish patient records to a healthcare practitioner
33	designated by the patient upon the request of the patient; and
34	(4) Maintain records of all patients receiving services under
35	this section for two (2) years.

36

1	SECT	ION	4. DO	NOT	CODII	Y.	Effect	ive date	<u>.</u>	
2	This	act	takes	effe	ct or	n and	after	January	1,	2022.
3										
4										
5										
6										
7										
8										
9										
10										
11										
12										
13										
14										
15										
16										
17										
18										
19										
20										
21										
22										
23										
24										
25										
26										
27										
28										
29										
30										
31										
32										
33										
34										
35										

36